Rate_NN of_IN Hepatitis_NP B_NP Virus_NP Infection_NP in_IN Pregnant_NP Women_NP Determined_NP by_IN a_DT Monoclonal_NP Hepatitis_NP B_NP Surface_NP Antigen_NP Immunoassay_NP The_DT rate_NN of_IN HBsAg_NP in_IN 6,976_CD B-human_NP chorionic_JJ gonadotropin_NN (B-hCG)-positive_JJ specimens_NNS ,_, as_RB determined_VBN by_IN the_DT Auszyme_NP Monoclonal_NP assay_NN (_( Abbott_NP Laboratories_NP ,_, Abbott_NP Park_NP ,_, Ill._NP )_) ,_, was_VBD 0.56_CD %_NN (_( 39_CD of_IN 6,986_CD repeatedly_RB reactive_JJ [_SYM RR_NP ]_SYM and_CC confirmed-positive_JJ specimens_NNS )_) ._SENT All_DT RR_NP and_CC confirmed_VBD specimens_NNS were_VBD hepatitis_NP B_NP virus_NN positive_JJ by_IN at_IN least_JJS one_CD additional_JJ test_NN ,_, yielding_VBG an_DT assay_NN specificity_NN of_IN 99.96_CD %_NN ._SENT The_DT findings_NNS argue_VBP against_IN unique_JJ attributes_NNS in_IN the_DT pregnant_JJ population_NN that_WDT might_MD produce_VB inaccurate_JJ assay_NN results_NNS ._SENT An_DT estimated_JJ 20,000_CD infants_NNS are_VBP born_VBN to_TO HBsAg-positive_JJ women_NNS in_IN the_DT United_NP States_NPS each_DT year_NN ._SENT Because_IN these_DT infants_NNS are_VBP at_IN high_JJ risk_NN of_IN perinatal_JJ hepatitis_NP B_NP virus_NN (_( HBV_NP )_) infection_NN ,_, chronic_JJ HBV_NP infection_NN ,_, and_CC chronic_JJ liver_NN disease_NN ,_, the_DT American_NP College_NP of_IN Obstetricians_NP and_CC Gynecologists_NP ,_, the_DT American_NP Academy_NP of_IN Family_NP Practices_NPS ,_, the_DT American_NP Academy_NP of_IN Pediatrics_NP ,_, and_CC the_DT Centers_NPS for_IN Disease_NP Control_NP and_CC Prevention_NP (_( CDC_NP )_) Advisory_NP Committee_NP on_IN Immunization_NP Practices_NPS have_VBP recommended_VBN that_IN all_DT pregnant_JJ women_NNS undergo_VBP testing_NN for_IN HBsAg_NP prior_RB to_TO delivery_NN ._SENT The_DT objective_NN of_IN this_DT study_NN was_VBD to_TO examine_VB the_DT rate_NN of_IN HBV_NP infection_NN in_IN specimens_NNS from_IN pregnant_JJ females_NNS using_VBG the_DT Auszyme_NP Monoclonal_NP assay_NN ._SENT We_PP investigated_VBD whether_IN pregnancy_NN had_VBD any_DT potential_JJ influence_NN on_IN the_DT specificity_NN of_IN the_DT Auszyme_NP Monoclonal_NP assay_NN results_NNS by_IN performing_VBG the_DT study_NN under_IN conditions_NNS that_WDT minimized_VBD sample_NN cross-contamination_NN and_CC by_IN using_VBG additional_JJ HBV_NP marker_NN verification_NN of_IN positive_JJ samples_NNS ._SENT In_IN phase_VB I_PP of_IN this_DT study_NN ,_, all_DT specimens_NNS were_VBD from_IN females_NNS and_CC were_VBD B-human_NP chorionic_JJ gonadotropin_NN (B-hCG)-positive_JJ sera_NN or_CC plasma_NN specimens_NNS at_IN the_DT reference_NN laboratory_NN ,_, had_VBD a_DT volume_NN of_IN 2_CD ml_NN or_CC greater_JJR ,_, and_CC had_VBD not_RB passed_VBN through_IN a_DT viral_JJ accessioning_VBG or_CC testing_VBG area_NN ._SENT The_DT reference_NN laboratory_NN (_( Quest_NP Diagnostics_NP ,_, Teterboro_NP ,_, N.J._NP )_) aliquoted_VBD each_DT sample_NN from_IN the_DT main_JJ specimen_NN tube_NN ,_, marked_VBD each_DT sample_NN vial_NN with_IN the_DT qualitative_JJ or_CC quantitative_JJ B-hCG_NP result_NN and_CC a_DT unique_JJ identifier_NN number_NN ,_, and_CC shipped_VBD the_DT samples_NNS by_IN overnight_JJ delivery_NN to_TO Abbott_NP Laboratories_NPS ._SENT The_DT Auszyme_NP Monoclonal_NP assay_NN was_VBD performed_VBN on_IN all_DT samples_NNS in_IN accordance_NN with_IN procedure_NN C_NP (_( incubation_NN at_IN 40C_JJ for_IN 75_CD min_NN )_) of_IN the_DT package_NN insert_NN ._SENT Initially_RB reactive_JJ samples_NNS were_VBD tested_VBN again_RB in_IN duplicate_NN ._SENT If_IN neither_DT of_IN the_DT repeat_NN tests_NNS was_VBD reactive_JJ ,_, the_DT specimen_NN was_VBD considered_VBN negative_JJ for_IN HBsAg_NP ._SENT If_IN either_DT retest_NN was_VBD reactive_JJ ,_, the_DT sample_NN was_VBD considered_VBN repeatedly_RB reactive_JJ (_( RR_NP )_) and_CC was_VBD then_RB tested_VBN by_IN the_DT Auszyme_NP confirmatory_JJ assay_NN through_IN procedure_NN A._NP Only_RB those_DT specimens_NNS for_IN which_WDT RR_NP results_NNS were_VBD neutralized_VBN by_IN the_DT confirmatory_JJ procedure_NN were_VBD considered_VBN positive_JJ for_IN HBsAg_NP (_( HBsAg_NP confirmatory_JJ assay_NN package_NN insert_NN [_SYM dated_VBN 1995_CD ]_SYM ,_, Abbott_NP Laboratories_NPS Diagnostics_NP Division_NP ,_, Abbott_NP Park_NP ,_, Ill._NP )_) ._SENT These_DT confirmed_VBN HBsAg-positive_JJ specimens_NNS were_VBD then_RB tested_VBN by_IN two_CD additional_JJ licensed_JJ HBsAg_NP assays_NNS :_: the_DT IMx_NP HBsAg_NP assay_NN (_( Abbott_NP Laboratories_NP )_) ,_, an_DT automated_JJ microparticle-based_JJ assay_NN with_IN a_DT monoclonal_NN antibody_NN capture_NN phase_NN and_CC an_DT enzyme-linked_JJ polyclonal_JJ antibody_NN detection_NN phase_NN ,_, and_CC the_DT Ortho_NP Antibody_NN to_TO HBsAg_NP ELISA_NP Test_NP System_NP 2_CD (_( Ortho-Clinical_NP Diagnostics_NP ,_, Raritan_NP ,_, N.J._NP )_) ,_, a_DT microtiter_NN assay_NN using_VBG monoclonal_NN antibody_NN capture_NN on_IN the_DT solid_JJ phase_NN and_CC an_DT enzyme-linked_JJ monoclonal_NN antibody_NN detection_NN phase_NN ._SENT Additional_JJ tests_NNS were_VBD performed_VBN according_VBG to_TO the_DT manufacturer_NN 's_POS package_NN insert_NN when_WRB there_EX was_VBD sufficient_JJ sample_NN volume_NN ._SENT These_DT tests_NNS included_VBD the_DT CORAB_NP radioimmunoassay_NP (_( Abbott_NP Laboratories_NP )_) ,_, which_WDT detects_VBZ HBV_NP core_JJ protein-specific_JJ antibody_NN ;_: the_DT HBe_NP EIA_NP (_( Abbott_NP Laboratories_NP )_) ,_, which_WDT detects_VBZ HBeAg_NP ;_: and_CC an_DT in-house_JJ research_NN assay_NN for_IN HBV_NP DNA_NP that_WDT uses_VBZ nested_VBN PCR_NP ._SENT Phase_VB II_NP of_IN the_DT study_NN was_VBD carried_VBN out_RP by_IN Abbott_NP Laboratories_NPS and_CC the_DT Laboratory_NP Corporation_NP of_IN America_NP (_( LabCorp_NP ,_, Elmhurst_NP ,_, Ill._NP )_) reference_NN laboratory_NN ._SENT B-hCG-positive_JJ specimens_NNS provided_VBN by_IN New_NP York_NP Biologics_NP ,_, Inc._NP (_( New_NP York_NP ,_, N.Y._NP )_) ,_, were_VBD collected_VBN using_VBG the_DT same_JJ criteria_NNS employed_VBN in_IN phase_NN I_PP of_IN this_DT study_NN ,_, along_RB with_IN a_DT signed_VBN patient_JJ informed-consent_JJ form_NN ._SENT Aliquots_NNS of_IN the_DT same_JJ sample_NN were_VBD shipped_VBN in_IN parallel_NN both_CC to_TO Abbott_NP Laboratories_NP and_CC to_TO the_DT LabCorp_NP reference_NN laboratory_NN ,_, where_WRB the_DT Auszyme_NP Monoclonal_NP assay_NN was_VBD performed_VBN on_IN all_DT samples_NNS ._SENT Any_DT initially_RB reactive_JJ ,_, RR_NP ,_, or_CC confirmed-reactive_JJ sample_NN identified_VBN at_IN LabCorp_NP was_VBD then_RB tested_VBN at_IN Abbott_NP Laboratories_NPS using_VBG the_DT pristine_JJ parallel_JJ sample_NN ._SENT Discordant_JJ samples_NNS between_IN the_DT two_CD sites_NNS were_VBD subjected_VBN to_TO the_DT testing_NN described_VBN for_IN phase_NN I_PP above_RB ._SENT New_NP York_NP Biologics_NP requested_VBD that_IN samples_NNS showing_VBG a_DT low-level_JJ reaction_NN ,_, i.e._FW an_DT Auszyme_NP sample-to-cutoff_NN ratio_NN between_IN 1_CD and_CC 2_CD ,_, be_VB redrawn_NN from_IN the_DT patients_NNS ._SENT The_DT redrawn_NN samples_NNS were_VBD evaluated_VBN in_IN the_DT same_JJ manner_NN as_IN the_DT initial_JJ samples_NNS ._SENT A_DT population_NN size_NN of_IN 1,286_CD would_MD be_VB needed_VBN to_TO statistically_RB validate_VB an_DT assay_NN showing_VBG a_DT 0.4_CD %_NN rate_NN of_IN prenatal_JJ HBV_NP infection_NN ,_, which_WDT is_VBZ the_DT lowest_JJS rate_NN reported_VBD by_IN the_DT CDC_NP (_( upper_JJ and_CC lower_JJR limits_NNS of_IN 0.0067_CD and_CC 0.0021_CD ,_, respectively_RB ,_, at_IN a_DT confidence_NN level_NN of_IN 95_CD %_NN with_IN binomial_JJ distribution_NN )_) ._SENT In_IN case_NN the_DT rates_NNS of_IN prenatal_JJ HBV_NP infection_NN had_VBD dropped_VBN significantly_RB since_IN the_DT original_JJ CDC_NP report_NN in_IN 1994_CD ,_, we_PP chose_VBD to_TO assume_VB the_DT possibility_NN of_IN a_DT 10-fold-lower_JJ infection_NN prevalence_NN of_IN 0.04_CD %_NN to_TO establish_VB the_DT number_NN of_IN specimens_NNS needed_VBN for_IN the_DT study_NN ._SENT The_DT targeted_JJ study_NN population_NN sizes_NNS of_IN 5,000_CD for_IN phase_NN I_PP and_CC 2,000_CD for_IN phase_NN II_NP would_MD represent_VB the_DT midpoint_NN of_IN the_DT population_NN size_NN required_VBN to_TO validate_VB a_DT prenatal_JJ HBV_NP infection_NN rate_NN of_IN 0.04_CD %_NN (_( 6,762_CD specimens_NNS at_IN the_DT 95_CD %_NN confidence_NN level_NN with_IN binomial_JJ distribution_NN )_) ._SENT Auszyme_NP Monoclonal_NP assay_NN specificity_NN was_VBD determined_VBN using_VBG the_DT following_VBG formula_NN :_: specificity_NN =_SYM (_( number_NN of_IN true-negative_JJ specimens/[number_NN of_IN true-negative_JJ specimens_NNS +_SYM number_NN of_IN false-positive_JJ specimens_NNS ]_SYM )_) x_SYM 100_CD ._SENT During_IN phase_VB I_PP of_IN the_DT study_NN ,_, 4,988_CD specimens_NNS were_VBD received_VBN and_CC tested_VBN ._SENT Of_IN these_DT samples_NNS ,_, 34_CD (_( 0.68_CD %_NN )_) were_VBD RR_NP specimens_NNS and_CC 31_CD of_IN the_DT 34_CD (_( 0.62_CD %_NN of_IN the_DT total_JJ sample_NN population_NN )_) were_VBD neutralized_VBN in_IN the_DT confirmatory_JJ assay_NN and_CC considered_VBN positive_JJ for_IN HBsAg_NP ._SENT All_DT 31_CD of_IN the_DT Auszyme_NP Monoclonal_NP HBsAg-positive_NP specimens_NNS were_VBD reactive_JJ by_IN the_DT IMx_NP HBsAg_NP assay_NN ._SENT Thirty_CD of_IN these_DT specimens_NNS were_VBD also_RB either_RB reactive_JJ by_IN the_DT Ortho_NP Antibody_NN to_TO HBsAg_NP ELISA_NP Test_NP System_NP 2_CD or_CC reactive_JJ by_IN testing_VBG for_IN another_DT HBV_NP marker_NN ._SENT Therefore_RB ,_, all_DT Auszyme_NP Monoclonal_NP HBsAg-positive_NP specimens_NNS were_VBD confirmed_VBN by_IN at_IN least_JJS one_CD additional_JJ HBV_NP marker_NN test_NN ._SENT Table_NN summarizes_VBZ the_DT RR_NP and_CC confirmatory_JJ rates_NNS for_IN the_DT phase_NN I_PP study_VBP ._SENT The_DT HBV_NP marker_NN profile_NN for_IN the_DT phase_NN I_PP specimens_NNS is_VBZ shown_VBN in_IN Table_NP ._SENT The_DT rate_NN of_IN RR_NP ,_, nonconfirmed_JJ specimens_NNS was_VBD 0.06_CD %_NN (_( 3_CD of_IN 4,988_CD specimens_NNS )_) ._SENT TABLE_NN 1_CD |_SYM RR_NP ,_, confirmed_VBD prenatal_JJ specimens_NNS from_IN study_NN phases_NNS I_PP and_CC II_NP TABLE_NP 2_CD |_SYM Detailed_JJ HBV_NP test_NN results_NNS for_IN RR_NP ,_, prenatal_JJ specimens_NNS from_IN study_NN phase_NN I_PP (_( n_NN =_SYM 34_CD )_) In_IN phase_NN II_NP of_IN the_DT study_NN ,_, 1,998_CD specimens_NNS were_VBD tested_VBN by_IN the_DT Auszyme_NP Monoclonal_NP assay_NN at_IN the_DT LabCorp_NP reference_NN laboratory_NN ._SENT The_DT rates_NNS of_IN RR_NP and_CC confirmed-positive_JJ specimens_NNS for_IN this_DT part_NN of_IN the_DT study_NN are_VBP shown_VBN in_IN Table_NP ._SENT Nine_CD specimens_NNS were_VBD RR_NP at_IN LabCorp_NP ._SENT All_DT nine_CD samples_NNS were_VBD RR_NP again_RB when_WRB they_PP were_VBD tested_VBN at_IN Abbott_NP Laboratories_NPS ,_, indicating_VBG an_DT RR_NP rate_NN of_IN 0.45_CD %_NN ._SENT Of_IN these_DT nine_CD RR_NP specimens_NNS ,_, one_CD specimen_NN was_VBD RR_NP and_CC confirmed_VBD to_TO be_VB positive_JJ at_IN LabCorp_NP but_CC was_VBD not_RB confirmed_VBN to_TO be_VB a_DT neat_JJ specimen_NN at_IN Abbott_NP ._SENT This_DT sample_NN had_VBD to_TO be_VB tested_VBN in_IN the_DT HBsAg_NP confirmatory_JJ assay_NN at_IN a_DT 1:25_CD dilution_NN ,_, due_JJ to_TO insufficient_JJ sample_NN volume_NN ,_, which_WDT may_MD provide_VB an_DT explanation_NN for_IN the_DT lack_NN of_IN confirmation_NN ._SENT A_DT second_JJ sample_NN was_VBD redrawn_NN from_IN this_DT patient_JJ 4_CD months_NNS after_IN the_DT initial_JJ sample_NN collection_NN ._SENT The_DT Auszyme_NP Monoclonal_NP assay_NN result_NN was_VBD negative_JJ for_IN the_DT redrawn_NN specimen_NN ,_, while_IN the_DT CORAB_NP result_NN was_VBD positive_JJ ,_, suggesting_VBG that_IN the_DT original_JJ specimen_NN was_VBD truly_RB HBsAg_NP positive_NN ._SENT Of_IN the_DT 6,986_CD prenatal_JJ specimens_NNS from_IN both_DT phases_NNS of_IN the_DT study_NN ,_, the_DT overall_JJ rate_NN of_IN RR_NP specimens_NNS was_VBD 0.62_CD %_NN (_( 43_CD of_IN 6,986_CD specimens_NNS )_) and_CC the_DT rate_NN of_IN RR_NP and_CC confirmed-positive_JJ specimens_NNS was_VBD 0.56_CD %_NN (_( 39_CD of_IN 6,986_CD specimens_NNS )_) ._SENT Under_IN these_DT conditions_NNS ,_, the_DT specificity_NN of_IN the_DT Auszyme_NP Monoclonal_NP assay_NN was_VBD 99.96_CD %_NN [_SYM 6,947_CD of_IN (_( 6,947_CD +_SYM 3_LS )_) specimens_NNS ]_SYM ,_, with_IN a_DT 95_CD %_NN confidence_NN interval_NN of_IN 99.87_CD to_TO 99.99_CD %_NN by_IN binomial_JJ distribution_NN ._SENT Licensed_JJ HBsAg_NP tests_NNS have_VBP a_DT very_RB high_JJ specificity_NN and_CC sensitivity_NN if_IN reactive_JJ tests_NNS are_VBP repeated_VBN and_CC confirmed_VBN by_IN neutralization_NN ,_, as_IN is_VBZ recommended_VBN by_IN the_DT manufacturers_NNS ._SENT However_RB ,_, non-RR_NP or_CC unconfirmed_JJ (nonneutralized)-reactive_JJ tests_NNS do_VBP occur_VB ._SENT There_EX are_VBP a_DT number_NN of_IN possible_JJ reasons_NNS for_IN such_JJ results_NNS ._SENT First_RB ,_, the_DT patient_NN may_MD have_VB an_DT immune_JJ response_NN to_TO a_DT vaccine_NN ._SENT Second_RB ,_, there_EX might_MD be_VB positive_JJ interference_NN in_IN the_DT mouse_NN monoclonal_NN antibody-based_JJ immunoassays_NNS caused_VBN by_IN the_DT presence_NN of_IN human_JJ anti-mouse_NN antibodies_NNS ._SENT The_DT most_RBS common_JJ cause_NN of_IN human_JJ anti-mouse_NN antibody_NN interference_NN is_VBZ prior_RB use_NN of_IN mouse_NN monoclonal_NN antibodies_NNS for_IN therapeutic_JJ or_CC imaging_NN purposes_NNS ._SENT Third_JJ ,_, a_DT technician_NN may_MD perform_VB a_DT laboratory_NN technique_NN improperly_RB ,_, such_JJ as_IN washing_VBG beads_NNS incorrectly_RB or_CC failing_VBG to_TO remove_VB particulate_JJ matter_NN from_IN specimens_NNS prior_RB to_TO testing_VBG (_( Auszyme_NP Monoclonal_NP package_NN insert_NN [_SYM dated_VBN 1995_CD ]_SYM ,_, Abbott_NP Laboratories_NPS Diagnostics_NP Division_NP )_) ._SENT Fourth_JJ ,_, truly_RB cross-reactive_JJ endogenous_JJ proteins_NNS may_MD be_VB present_JJ in_IN the_DT specimen_NN ._SENT Neutralized_VBN ,_, RR_NP specimens_NNS that_WDT do_VBP not_RB correlate_VB with_IN the_DT negative_JJ disease_NN status_NN of_IN a_DT patient_NN exist_VBP ._SENT In_IN these_DT cases_NNS ,_, nonreactive_JJ specimens_NNS may_MD be_VB contaminated_VBN by_IN the_DT transfer_NN of_IN antigen_NN from_IN positive_JJ samples_NNS ,_, either_CC through_IN soiled_VBN equipment_NN or_CC the_DT aerosolized_JJ transfer_NN of_IN antigen_NN (_( Auszyme_NP Monoclonal_NP package_NN insert_NN [_SYM dated_VBN 1995_CD ]_SYM and_CC unpublished_JJ data_NNS ,_, Abbott_NP Laboratories_NPS Diagnostics_NP Division_NP )_) ._SENT The_DT proportion_NN of_IN high-risk_JJ individuals_NNS in_IN a_DT previously_RB reported_VBN study_NN population_NN might_MD have_VB increased_VBN the_DT likelihood_NN of_IN sample_NN cross-contamination_NN ,_, resulting_VBG in_IN an_DT unusually_RB high_JJ rate_NN of_IN false-positive_JJ test_NN results_NNS with_IN the_DT Auszyme_NP Monoclonal_NP assay_NN ._SENT In_IN rare_JJ cases_NNS transient_JJ (_( neutralizable_JJ )_) antigenemia_NN has_VBZ been_VBN reported_VBN for_IN both_DT adults_NNS and_CC infants_NNS postvaccination_NN with_IN HBV_NP vaccine_NN ._SENT In_IN these_DT cases_NNS ,_, assays_NNS detect_VBP residual_JJ vaccine_NN ._SENT Due_JJ to_TO the_DT above-listed_JJ factors_NNS ,_, there_EX is_VBZ some_DT concern_NN that_IN routine_JJ prenatal_JJ testing_NN may_MD lead_VB to_TO an_DT increase_NN in_IN the_DT number_NN of_IN enzyme_NN immunoassay_NN false-positive_JJ results_NNS in_IN what_WP is_VBZ perceived_VBN as_IN a_DT low-risk_JJ population_NN ._SENT This_DT study_NN was_VBD designed_VBN to_TO determine_VB the_DT rate_NN of_IN HBV_NP infection_NN in_IN a_DT general_JJ pregnant_JJ population_NN and_CC to_TO evaluate_VB the_DT suitability_NN of_IN the_DT Auszyme_NP Monoclonal_NP assay_NN for_IN widespread_JJ prenatal_JJ HBV_NP screening_NN ._SENT The_DT approach_NN was_VBD to_TO use_VB specimens_NNS that_WDT had_VBD never_RB passed_VBN through_IN a_DT viral_JJ testing_NN laboratory_NN area_NN and_CC were_VBD not_RB likely_JJ to_TO have_VB been_VBN exposed_VBN to_TO cross-contamination_NN by_IN HBV-reactive_JJ samples_NNS ._SENT Moreover_RB ,_, several_JJ independent_JJ markers_NNS for_IN HBV_NP were_VBD determined_VBN for_IN the_DT HBsAg-reactive_JJ specimens_NNS to_TO provide_VB a_DT profile_NN of_IN the_DT infection_NN stage_NN ._SENT Finally_RB ,_, in_IN phase_NN II_NP of_IN this_DT study_NN ,_, the_DT positive_JJ samples_NNS were_VBD evaluated_VBN in_IN parallel_NN by_IN two_CD separate_JJ testing_NN sites_NNS ,_, which_WDT yielded_VBD equivalent_JJ enzyme_NN immunoassay_NN results_NNS ._SENT The_DT results_NNS reported_VBD here_RB for_IN the_DT Auszyme_NP Monoclonal_NP assay_NN indicate_VBP an_DT overall_JJ RR_NP rate_NN of_IN 0.62_CD %_NN and_CC an_DT RR_NP ,_, confirmed_VBD rate_NN (_( determined_VBN as_IN recommended_VBN by_IN the_DT manufacturer_NN )_) of_IN 0.56_CD %_NN ,_, with_IN an_DT RR_NP ,_, nonconfirmed_JJ rate_NN of_IN only_RB 0.04_CD %_NN ._SENT All_DT of_IN the_DT RR_NP ,_, confirmed-positive_JJ specimens_NNS that_WDT had_VBD sufficient_JJ volume_NN to_TO undergo_VB any_DT further_JJR testing_NN were_VBD confirmed_VBN to_TO be_VB truly_RB positive_JJ by_IN at_IN least_JJS one_CD additional_JJ test_NN from_IN a_DT panel_NN of_IN tests_NNS that_WDT are_VBP indicative_JJ of_IN viral_JJ load_NN or_CC different_JJ stages_NNS of_IN HBV_NP infection_NN ._SENT Based_VBN on_IN these_DT data_NNS ,_, the_DT specificity_NN of_IN the_DT Auszyme_NP Monoclonal_NP assay_NN is_VBZ 99.96_CD %_NN ._SENT The_DT overall_JJ HBsAg_NP prevalence_NN rate_NN obtained_VBN in_IN this_DT study_NN ,_, 0.56_CD %_NN ,_, is_VBZ in_IN excellent_JJ agreement_NN with_IN the_DT 0.50_CD %_NN rate_NN of_IN positive_JJ HBsAg_NP tests_NNS reported_VBD by_IN the_DT CDC_NP when_WRB results_NNS from_IN several_JJ studies_NNS involving_VBG pregnant_JJ women_NNS were_VBD averaged_VBN ._SENT Three_CD different_JJ HBsAg_NP assay_NN formats_NNS and_CC multiple-marker_NN verification_NN of_IN the_DT RR_NP ,_, confirmed_VBD specimens_NNS suggest_VBP that_IN there_EX is_VBZ no_DT unique_JJ factor_NN associated_VBN with_IN pregnancy_NN which_WDT led_VBD to_TO an_DT RR_NP ,_, confirmed_VBD specimen_NN that_WDT was_VBD not_RB truly_RB positive_JJ ._SENT In_IN conclusion_NN ,_, in_IN the_DT present_JJ study_NN ,_, the_DT rate_NN of_IN HBV_NP infection_NN in_IN a_DT total_NN of_IN 6,986_CD specimens_NNS obtained_VBN from_IN pregnant_JJ females_NNS was_VBD 0.56_CD %_NN ,_, a_DT value_NN that_WDT agrees_VBZ well_RB with_IN prior_JJ CDC_NP estimates_NNS for_IN this_DT population_NN ._SENT 